vs
Prestige Consumer Healthcare Inc.（PBH）与PROGRESS SOFTWARE CORP（PRGS）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是PROGRESS SOFTWARE CORP的1.1倍（$283.4M vs $252.7M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 10.2%，领先6.3%），PROGRESS SOFTWARE CORP同比增速更快（17.5% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $59.9M），过去两年PROGRESS SOFTWARE CORP的营收复合增速更高（17.0% vs 1.2%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
Progress Software是全球领先的企业级软件服务商，主营应用开发平台、数据连接工具、数字体验解决方案等产品，服务覆盖金融、医疗、制造、零售等多行业的全球企业客户，助力客户搭建高性能可扩展的业务应用，提升运营效率。
PBH vs PRGS — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $252.7M |
| 净利润 | $46.7M | $25.7M |
| 毛利率 | 55.5% | 81.6% |
| 营业利润率 | 29.1% | 15.2% |
| 净利率 | 16.5% | 10.2% |
| 营收同比 | -2.4% | 17.5% |
| 净利润同比 | -23.5% | 2144.6% |
| 每股收益（稀释后） | $0.97 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $283.4M | $252.7M | ||
| Q3 25 | $274.1M | $249.8M | ||
| Q2 25 | $249.5M | $237.4M | ||
| Q1 25 | $296.5M | $238.0M | ||
| Q4 24 | $290.3M | $215.0M | ||
| Q3 24 | $283.8M | $178.7M | ||
| Q2 24 | $267.1M | $175.1M | ||
| Q1 24 | $277.0M | $184.7M |
| Q4 25 | $46.7M | $25.7M | ||
| Q3 25 | $42.2M | $19.4M | ||
| Q2 25 | $47.5M | $17.0M | ||
| Q1 25 | $50.1M | $10.9M | ||
| Q4 24 | $61.0M | $1.1M | ||
| Q3 24 | $54.4M | $28.5M | ||
| Q2 24 | $49.1M | $16.2M | ||
| Q1 24 | $49.5M | $22.6M |
| Q4 25 | 55.5% | 81.6% | ||
| Q3 25 | 55.3% | 81.0% | ||
| Q2 25 | 56.2% | 80.1% | ||
| Q1 25 | 57.3% | 80.6% | ||
| Q4 24 | 55.5% | 83.0% | ||
| Q3 24 | 55.5% | 83.7% | ||
| Q2 24 | 54.7% | 81.7% | ||
| Q1 24 | 54.8% | 82.2% |
| Q4 25 | 29.1% | 15.2% | ||
| Q3 25 | 29.1% | 17.6% | ||
| Q2 25 | 28.8% | 16.3% | ||
| Q1 25 | 29.8% | 13.6% | ||
| Q4 24 | 31.7% | 10.0% | ||
| Q3 24 | 29.7% | 22.6% | ||
| Q2 24 | 27.0% | 15.5% | ||
| Q1 24 | 29.7% | 19.0% |
| Q4 25 | 16.5% | 10.2% | ||
| Q3 25 | 15.4% | 7.8% | ||
| Q2 25 | 19.0% | 7.2% | ||
| Q1 25 | 16.9% | 4.6% | ||
| Q4 24 | 21.0% | 0.5% | ||
| Q3 24 | 19.2% | 15.9% | ||
| Q2 24 | 18.4% | 9.2% | ||
| Q1 24 | 17.9% | 12.3% |
| Q4 25 | $0.97 | $0.59 | ||
| Q3 25 | $0.86 | $0.44 | ||
| Q2 25 | $0.95 | $0.39 | ||
| Q1 25 | $1.00 | $0.24 | ||
| Q4 24 | $1.22 | $0.01 | ||
| Q3 24 | $1.09 | $0.65 | ||
| Q2 24 | $0.98 | $0.37 | ||
| Q1 24 | $0.98 | $0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $94.8M |
| 总债务越低越好 | $1.0B | $1.4B |
| 股东权益账面价值 | $1.8B | $478.3M |
| 总资产 | $3.5B | $2.5B |
| 负债/权益比越低杠杆越低 | 0.56× | 2.93× |
8季度趋势，按日历期对齐
| Q4 25 | $62.4M | $94.8M | ||
| Q3 25 | $119.1M | $99.0M | ||
| Q2 25 | $139.5M | $102.0M | ||
| Q1 25 | $97.9M | $124.2M | ||
| Q4 24 | $50.9M | $118.1M | ||
| Q3 24 | $51.5M | $232.7M | ||
| Q2 24 | $34.3M | $190.4M | ||
| Q1 24 | $46.5M | $133.2M |
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $993.1M | $1.4B | ||
| Q2 25 | $992.7M | $1.5B | ||
| Q1 25 | $992.4M | $1.5B | ||
| Q4 24 | $992.0M | $1.5B | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $1.8B | $478.3M | ||
| Q3 25 | $1.8B | $477.7M | ||
| Q2 25 | $1.9B | $452.7M | ||
| Q1 25 | $1.8B | $431.8M | ||
| Q4 24 | $1.8B | $438.8M | ||
| Q3 24 | $1.7B | $425.6M | ||
| Q2 24 | $1.7B | $401.7M | ||
| Q1 24 | $1.7B | $461.7M |
| Q4 25 | $3.5B | $2.5B | ||
| Q3 25 | $3.4B | $2.4B | ||
| Q2 25 | $3.4B | $2.4B | ||
| Q1 25 | $3.4B | $2.5B | ||
| Q4 24 | $3.3B | $2.5B | ||
| Q3 24 | $3.3B | $1.6B | ||
| Q2 24 | $3.3B | $1.6B | ||
| Q1 24 | $3.3B | $1.5B |
| Q4 25 | 0.56× | 2.93× | ||
| Q3 25 | 0.54× | 2.97× | ||
| Q2 25 | 0.54× | 3.22× | ||
| Q1 25 | 0.54× | 3.50× | ||
| Q4 24 | 0.55× | 3.48× | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $62.8M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | $59.9M |
| 自由现金流率自由现金流/营收 | 26.6% | 23.7% |
| 资本支出强度资本支出/营收 | 1.1% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.68× | 2.44× |
| 过去12个月自由现金流最近4个季度 | $267.2M | $229.5M |
8季度趋势，按日历期对齐
| Q4 25 | $78.3M | $62.8M | ||
| Q3 25 | $57.5M | $73.4M | ||
| Q2 25 | $79.0M | $30.0M | ||
| Q1 25 | $61.8M | $68.9M | ||
| Q4 24 | $65.1M | $19.7M | ||
| Q3 24 | $69.8M | $57.7M | ||
| Q2 24 | $54.8M | $63.7M | ||
| Q1 24 | $66.9M | $70.5M |
| Q4 25 | $75.3M | $59.9M | ||
| Q3 25 | $55.4M | $72.4M | ||
| Q2 25 | $78.2M | $29.5M | ||
| Q1 25 | $58.4M | $67.7M | ||
| Q4 24 | $63.5M | $16.8M | ||
| Q3 24 | $67.8M | $56.6M | ||
| Q2 24 | $53.6M | $62.7M | ||
| Q1 24 | $63.8M | $70.2M |
| Q4 25 | 26.6% | 23.7% | ||
| Q3 25 | 20.2% | 29.0% | ||
| Q2 25 | 31.3% | 12.4% | ||
| Q1 25 | 19.7% | 28.4% | ||
| Q4 24 | 21.9% | 7.8% | ||
| Q3 24 | 23.9% | 31.7% | ||
| Q2 24 | 20.1% | 35.8% | ||
| Q1 24 | 23.0% | 38.0% |
| Q4 25 | 1.1% | 1.1% | ||
| Q3 25 | 0.8% | 0.4% | ||
| Q2 25 | 0.3% | 0.2% | ||
| Q1 25 | 1.2% | 0.5% | ||
| Q4 24 | 0.5% | 1.3% | ||
| Q3 24 | 0.7% | 0.6% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 1.1% | 0.2% |
| Q4 25 | 1.68× | 2.44× | ||
| Q3 25 | 1.36× | 3.78× | ||
| Q2 25 | 1.66× | 1.76× | ||
| Q1 25 | 1.23× | 6.30× | ||
| Q4 24 | 1.07× | 17.13× | ||
| Q3 24 | 1.28× | 2.03× | ||
| Q2 24 | 1.12× | 3.93× | ||
| Q1 24 | 1.35× | 3.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
